---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-023462"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:39:30.611070+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Verastem posts updated corporate presentation; no specific financial or clinical data disclosed in filing

## Summary
- Corporate presentation dated March 4, 2026, furnished as Exhibit 99.1 to Form 8-K.
- Presentation titled 'Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers'.
- No revenue, trial results, or other material metrics provided in the 8-K or the exhibit excerpt.

## SEC filing metadata
- accession: 0001104659-26-023462
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465926023462/0001104659-26-023462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465926023462/tm267866d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-023462
- JSON: https://secwatch.observer/filing/0001104659-26-023462.json
- Plain text: https://secwatch.observer/filing/0001104659-26-023462.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.